tbuckley/cabot-search huggingface dataset:
Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52
Authors: Sławomir Poletajew, Piotr Radziszewski, Juan Palou
Journal: European Urology (2016)
Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.
Authors: Charles G. Drake, David F. McDermott, Mario Sznol, Toni K. Choueiri, Harriet M. Kluger, John D. Powderly, David C. Smith, Vindira Sankar, Andres A. Gutierrez, Jon M. Wigginton, Georgia Kollia, Ashok Kumar Gupta, Michael B. Atkins
Journal: Journal of Clinical Oncology (2013)

4514 Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that negatively regulates T-cell activation. PD-L1, a PD-1 ligand, has been associated with poor prognosis in mRCC pts. In a phase I study of nivolumab, a PD-1 receptor blocking antibody, in pts with previously treated mRCC and other solid tumors, an MTD was not reached at 10 mg/kg IV Q2WK. Cohorts of mRCC pts were expanded at the 1 and 10 mg/kg dose levels. Methods: Pts received nivolumab for ≤12 cycles (4 doses/cycle) until unacceptable toxicity, progression, or complete response. We report overall survival (OS), updated response data, and long-term safety for the mRCC cohorts from a data analysis in July 2012. Results: 34 pts with mRCC were treated at 1 mg/kg (n=18) or 10 mg/kg (n=16). 44% of pts had received ≥3 prior therapies (74% prior antiangiogenic therapy; 59% prior immunotherapy). Median OS across doses has not yet been reached. Median duration of response was 12.9 months for both doses with 5 of the 10 responses lasting ≥1 year. The incidence of grade 3-4 related adverse events for the RCC cohort was 21% and included hypophosphatemia (6%) and respiratory disorders (6%), with no confirmed-drug related deaths or grade 3 pneumonitis. Treatment discontinuation due to drug-related AEs occurred in 18/304 (6%) of patients in the overall treated population. Conclusions: Nivolumab produced durable survival and responses in a subset of heavily pretreated mRCC pts, with an acceptable safety profile, even after long term continuous dosing. Overall survival appears promising for this population of pts. These findings provide the basis for an ongoing randomized phase III trial of nivolumab in mRCC (NCT01668784). Follow-up data through a February 2013 cutoff is being collected. Clinical trial information: NCT00730639. [Table: see text]
2016 Patellofemoral pain consensus statement from the 4th International Patellofemoral Pain Research Retreat, Manchester. Part 1: Terminology, definitions, clinical examination, natural history, patellofemoral osteoarthritis and patient-reported outcome measures
Authors: Kay M Crossley, Joshua J Stefanik, James Selfe, Natalie J Collins, Irene S Davis, Christopher M Powers, Jenny McConnell, Bill Vicenzino, David M Bazett-Jones, Jean-Francois Esculier, Dylan Morrissey, Michael J Callaghan
Journal: British Journal of Sports Medicine (2016)

Patellofemoral pain (PFP) typically presents as diffuse anterior knee pain, usually with activities such as squatting, running, stair ascent and descent. It is common in active individuals across the lifespan,1–4 and is a frequent cause for presentation at physiotherapy, general practice, orthopaedic and sports medicine clinics in particular.5 ,6 Its impact is profound, often reducing the ability of those with PFP to perform sporting, physical activity and work-related activities pain-free. Increasing evidence suggests that it is a recalcitrant condition, persisting for many years.7–9 In an attempt to share recent innovations, build on the first three successful biennial retreats and define the ‘state of the art’ for this common, impactful condition; the 4th International Patellofemoral Pain Research Retreat was convened.

The 4th International Patellofemoral Research Retreat was held in Manchester, UK, over 3 days (September 2–4th, 2015). After undergoing peer-review for scientific merit and relevance to the retreat, 67 abstracts were accepted for the retreat (50 podium presentations, and 17 short presentations). The podium and short presentations were grouped into five categories; (1) PFP, (2) factors that influence PFP (3) the trunk and lower extremity (4) interventions and (5) systematic analyses. Three keynote speakers were chosen for their scientific contribution in the area of PFP. Professor Andrew Amis spoke on the biomechanics of the patellofemoral joint. Professor David Felson spoke on patellofemoral arthritis,10 and Dr Michael Ratleff's keynote theme was PFP in the adolescent patient.11 As part of the retreat, we held structured, whole-group discussions in order to develop consensus relating to the work presented at the meeting as well as evidence gathered from the literature.

### Consensus development process

In our past three International Patellofemoral Research Retreats, we developed a consensus statement addressing different presentation categories.12–14 In Manchester in 2015, we revised the format. For the exercise and …
Case 24-1985
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Gilbert H. Mudge, John T. Fallon
Journal: New England Journal of Medicine (1985)

Presentation of CaseA 49-year-old man was admitted to the hospital after collapse at work.He was reportedly well until three weeks earlier, when he fell and sustained a laceration of the right leg. A physician noted that his blood pressure was 150/90 mm Hg but prescribed no antihypertensive medication. During the next few days the laceration bled intermittently. His condition was apparently stable thereafter until three days before admission, when a severe occipital headache developed and was accompanied by pain in both temporomandibular joints. He took two aspirins every four hours, without relief of pain. On the day of . . .
Changing patterns of psychiatric inpatient care in a university general hospital
Authors: R H Gervais, G W Barnard, J E Adams, E Gordon
Journal: American Journal of Psychiatry (1975)

The authors describe the changing patterns of psychiatric inpatient care in a university hospital. Patients are shortening their hospital stay and are traveling fewer miles from their homes to the hospital. Increasing numbers of blacks, men, and low-income persons are being treated. In addition, the percentage of patients with neuroses and transient situational disturbances has decreased, while the percentage of those with personality and behavior disorders has increased. The authors discuss the implications of these changes, which benefit both patients and the education of students.
Esophageal fishbone impaction as a result of ingestion of “trapoen” (Surinamese dried fish)
Authors: Mandhkani Mahajan, V. Spaander, J. van Lanschot
Journal: Endoscopy (2016)

A 47-year-old man from Surinam came to the emergency room because of a progressive burning chest pain. The pain had arisen acutely 2 days previously during dinner, increasing over time and restricting his oral intake because eating aggravated the pain.
Persisting transmission of carbapenemase-producing Klebsiella pneumoniae due to an environmental reservoir in a university hospital, France, 2012 to 2014
Authors: Béatrice Clarivet, Delphine Grau, Estelle Jumas-Bilak, Hélène Jean-Pierre, Alix Pantel, Sylvie Parer, Anne Lotthé
Journal: Eurosurveillance (2016)

In France, the proportion of episodes of carbapenemase-producing Enterobacteriaceae (CPE) with no recent stay or hospitalisation abroad is increasing. In this study, we investigate epidemiological links between apparently unrelated cases of OXA-48-producing Klebsiella pneumoniae (Kp OXA-48) colonisation or infection. We genotyped detected organisms by repetitive sequence-based PCR, and used a dynamic registry of cases and contacts to cross-reference patients' hospital stays. Between 1 November 2012 and 28 February 2014, 23 Kp OXA-48 cases were detected in a university hospital in Montpellier, of which 15 were involved in three outbreaks: outbreaks I and II occurred in November 2012 and outbreak III in October 2013. Molecular comparison of bacterial strains revealed clonal identity between cases involved in outbreaks II and III and four single cases. Cross-referencing of hospital stays revealed that these single cases and the index case of outbreak III had occupied the same room. Active case search among former occupants of that room found an additional Kp OXA-48 carrier. A clonal strain was isolated from the sink of that room. The epidemiological link between the contaminated room and outbreak II remained undetected. This study is a reminder that environmental reservoirs should be considered as a source of CPE transmission.
Adding to the transitional care evidence base for future national guidance
Authors: Janet E McDonagh, Albert Farre, Susie Aldiss, Katie Biggs, Fiona Campbell
Journal: BMJ (2016)

We wish to highlight a Cochrane review,1 published since the 2016 NICE guidance for transitional care,2 that concluded that evidence is limited on how transitional care should be delivered.1

Challenges to research are centred on evaluating a complex intervention that crosses medical, social, and educational disciplines, as …
Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis
Authors: Rakesh Bam, Sathisha Upparahalli Venkateshaiah, Xin Li, Sharmin Khan, Wen Ling, Randal S Shelton, Qing Zhang, Bart Barlogie, Joshua Epstein, Shmuel Yaccoby
Journal: Blood (2013)
Long non-coding RNAs in human early embryonic development and their potential in ART
Authors: Julien Bouckenheimer, Said Assou, Sébastien Riquier, Cyrielle Hou, Nicolas Philippe, Caroline Sansac, Thierry Lavabre-Bertrand, Thérèse Commes, Jean-Marc Lemaître, Anthony Boureux, John De Vos
Journal: Human Reproduction Update (2016)

Human long non-coding RNAs (lncRNAs) are an emerging category of transcripts with increasingly documented functional roles during development. LncRNAs and roles during human early embryo development have recently begun to be unravelled. This review summarizes the most recent knowledge on lncRNAs and focuses on their expression patterns and role during early human embryo development and in pluripotent stem cells (PSCs). Public mRNA sequencing (mRNA-seq) data were used to illustrate these expression signatures. The PubMed and EMBASE databases were first interrogated using specific terms, such as 'lncRNAs', to get an extensive overview on lncRNAs up to February 2016, and then using 'human lncRNAs' and 'embryo', 'development', or 'PSCs' to focus on lncRNAs involved in human embryo development or in PSC. Recently published RNA-seq data from human oocytes and pre-implantation embryos (including single-cell data), PSC and a panel of normal and malignant adult tissues were used to describe the specific expression patterns of some lncRNAs in early human embryos. The existence and the crucial role of lncRNAs in many important biological phenomena in each branch of the life tree are now well documented. The number of identified lncRNAs is rapidly increasing and has already outnumbered that of protein-coding genes. Unlike small non-coding RNAs, a variety of mechanisms of action have been proposed for lncRNAs. The functional role of lncRNAs has been demonstrated in many biological and developmental processes, including cell pluripotency induction, X-inactivation or gene imprinting. Analysis of RNA-seq data highlights that lncRNA abundance changes significantly during human early embryonic development. This suggests that lncRNAs could represent candidate biomarkers for developing non-invasive tests for oocyte or embryo quality. Finally, some of these lncRNAs are also expressed in human cancer tissues, suggesting that reactivation of an embryonic lncRNA program may contribute to human malignancies. LncRNAs are emerging potential key players in gene expression regulation. Analysis of RNA-seq data from human pre-implantation embryos identified lncRNA signatures that are specific to this critical step. We anticipate that further studies will show that these new transcripts are major regulators of embryo development. These findings might also be used to develop new tests/treatments for improving the pregnancy success rate in IVF procedures or for regenerative medicine applications involving PSC.
Incompatibility between Nuclear and Mitochondrial Genomes Contributes to an Interspecies Reproductive Barrier
Authors: Hong Ma, Nuria Marti Gutierrez, Robert Morey, Crystal Van Dyken, Eunju Kang, Tomonari Hayama, Yeonmi Lee, Ying Li, Rebecca Tippner-Hedges, Don P. Wolf, Louise C. Laurent, Shoukhrat Mitalipov
Journal: Cell Metabolism (2016)
Less Harmful Ways of Smoking&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: E L Wynder, D Hoffmann
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Less Harmful Ways of Smoking Get access Ernest L. Wynder, M.D., Ernest L. Wynder, M.D. American Health Foundation, New York, New York 10019 Search for other works by this author on: Oxford Academic PubMed Google Scholar Dietrich Hoffmann, Ph.D. Dietrich Hoffmann, Ph.D. American Health Foundation, New York, New York 10019 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 6, June 1972, Pages 1749–1758, https://doi.org/10.1093/jnci/48.6.1749 Published: 01 June 1972
Lymphomas With MYC-Translocation Other Than Burkitt’s Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases
Authors: Jose-Tomas Navarro, Maria Joao Baptista, Alejandra Martinez-Trillos, Gustavo Tapia, Jose Angel Hernandez-Rivas, Olga Garcia, Anna Muñoz-Marmol, Juan-Manuel Sancho, Fuensanta Millá, Evarist Feliu, Jose-Luis Mate, Armando Lopez-Guillermo, Josep-Maria Ribera
Journal: Blood (2013)
P63 Is data quality more important than data quantity in the diagnosis of occupational asthma from serial peak flow records?: Abstract P63 Table 1
Authors: VC Moore, CBSG Burge, AS Robertson, PS Burge
Journal: Thorax (2015)

<h3>Background</h3> Serial measurements of peak expiratory flow (PEF) are a recommended method for confirming a diagnosis of occupational asthma and are the only available method for low molecular weight agents available to many non-specialists. There is a tradeoff between accepting only measurements fulfilling quality standards with reduced data quantity and accepting all measurements irrespective of quality. We have investigated the effect of systematically reducing quality or quantity on the diagnostic sensitivity and specificity of these records in the diagnosis of occupational asthma using the Oasys system. <h3>Methods</h3> Serial PEF measurements from 36 specific inhalation challenge positive occupational asthmatics and 44 non-occupational asthmatics were used. Records contained 4 weeks of ≥ 4 PEF readings/day for 75% of days. PEFs were measured on metres without any data quality requirements. Data was corrupted in 2 ways: 1) Each PEF measurement was randomly changed to be up to +50 L/min or -50 L/min from the original value in increments of 10 L/min. Records were randomised 3 times and the sensitivity and specificity compared at each randomisation to the original using the Oasys score, area between curves (ABC) score and timepoint analysis. 2) Independently, the number of readings per day were reduced sequentially from ≥7 readings per day to 2 readings per day. The sensitivity and specificity of the Oasys score, area between curves (ABC) score and timepoint analysis were compared after each reduction. <h3>Results</h3> Random alteration of individual readings had small effects on sensitivity and specificity at each randomisation (Table 1). When the number of readings were reduced, the sensitivity of the Oasys score and ABC score was extremely robust in all reductions down to 3 readings per day. The sensitivity of the timepoint analysis was more affected. With only 2 readings, sensitivity was reduced for all scores. Specificity was unaffected by data reduction (Table 1). <h3>Conclusion</h3> Specificity was not reduced by adding random errors to the peak flow measurements nor through data reduction. Sensitivity was reduced, relatively more for the timepoint analysis, but in 2/3 randomisations it was preserved for the Oasys and ABC systems. Oasys analysis is robust despite decreasing data quality and quantity.
Upfront Allogeneic-Stem Cell Transplantation for Patients with Non-Localized Untreated Peripheral T-Cell Lymphoma: An Intention-to-Treat Analysis from a Single Center
Authors: Marion Loirat, Patrice Chevalier, Christophe Leux, Anne Moreau, Céline Bossard, Thierry Guillaume, Thomas Gastinne, Jacques Delaunay, Nicolas Blin, Beatrice Mahe, Viviane Dubruille, Karine Augel-Meunier, Pierre Peterlin, Herve Maisonneuve, Nadine Morineau, Philippe Moreau, Henry Jardel, Mohamad Mohty, Philippe Moreau, Steven Legouill
Journal: Blood (2014)
T-cell based cancer immunotherapy with a bispecific antibody directed at CD3 and EGFR
Authors: U. Reusch, S. Olson, J. Davis, P. Davol, M. Sundarum, P. Liu, L. G. Lum
Journal: Journal of Clinical Oncology (2005)

2552 Background: Epidermal growth factor receptor (EGFR) is expressed on various normal and malignant human tissues. Overexpression of EGFR and its role in proliferation of some malignant tumor cells make it a therapeutic target. Unfortunately, results from clinical trials suggest limited anti-tumor activity mediated by anti-EGFR (cetuximab) despite high affinity (HA) binding to the receptor. Exploiting this HA for for cytotoxic T cell therapy, we developed a bispecific antibody, EGFRBi, produced by chemical heteroconjugation of anti-CD3 and anti-EGFR, with which we then arm activated T cells (ATC). Methods: ATC from normal and patient donors were expanded ex vivo. Specific cytolytic activity of ATC armed with EGFRBi (50 ng/106 ATC; dose-titration optimized) against EGFR-expressing cell lines derived from lung (A549, Calu-6, IMR-90); pancreas (MIA PaCa-2, COLO 356/FG); colon (LS174T, HCT-8); brain (U-373 MG, U-87 MG; SK-N-MC); and skin (SCC-25, A431) or an EGFR-negative breast carcinoma (MDA-MB-453) was evaluated in Cr51 release assays. Results: At effector:target ratios (E:T) ranging from 3.125:1 to 50:1, EGFRBi-armed ATC induced significant cytotoxicity (23 to 79%, respectively) against all the EGFR+ cell lines compared to unarmed ATC, unconjugated mAbs, or ATC armed with an irrelevant BiAb (OKT3 x Rituximab, CD20Bi). No enhanced EGFRBi-armed ATC killing was noted against the EGFR- cells, and cytotoxicity was competitively blocked in the presence of cetuximab. After binding to EGFR+ tumor cells, EGFRBi-armed ATC secreted significantly higher levels of anti-tumor associated cytokines, IL2, RANTES, IFNγ and TNFα, compared to unarmed or CD20Bi-armed ATC. Conclusions: Our studies show significantly enhanced, specific cytotoxicity mediated by EGFRBi-armed ATC directed at multiple tumor cell lines expressing EGFR compared to treatment with unarmed ATC or cetuximab alone. Combining anti-EGFR antibody targeting with non-MHC restricted cytotoxicity of ATC into a single biologic drug may bypass limitations of receptor functional status when using cetuximab alone. These data and in vivo observations in an animal model provide the basis for phase I/II clinical trials using EGFRBi-armed ATC to target various tumor types. No significant financial relationships to disclose.
Comparison Of Intermittent and Continuous Dosing Regimens Of Pomalidomide In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial
Authors: Kartik Sehgal, Mehmet H. Kocoglu, Yanhong Deng, Rakesh Verma, Lin Zhang, Dennis L. Cooper, Xiaopan Yao, Kavita Dhodapkar, Madhav V. Dhodapkar
Journal: Blood (2013)
Mendelian randomization in (epi)genetic epidemiology: an effective tool to be handled with care
Authors: Antti Latvala, Miina Ollikainen
Journal: Genome biology (2016)

A study examining blood lipid traits takes epigenomics approaches to the next level by using carefully performed Mendelian randomization to assess causality rather than simply reporting associations. See related research article: http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1000-6
Recovery of oxidative stress-induced damage in Cisd2-deficient cardiomyocytes by sustained release of ferulic acid from injectable hydrogel
Authors: Yung-Hsin Cheng, Feng-Huei Lin, Chien-Ying Wang, Chen-Yuan Hsiao, Hung-Ching Chen, Hsin-Yu Kuo, Ting-Fen Tsai, Shih-Hwa Chiou
Journal: Biomaterials (2016)
Case 31-1963
Authors: Jack R. Dreyfuss, Benjamin Castleman
Journal: New England Journal of Medicine (1963)

Presentation of CaseA fifty-nine-year-old woman entered the hospital because of vomiting.Five weeks before entry the patient began to have abdominal fullness, intermittent crampy pain in the middle portion of the abdomen, increasing constipation and nausea with vomiting. These symptoms persisted, although the pain was never severe, and she was able to take a small amount of liquid by mouth without vomiting. There was no history of melena, hematemesis or previous abdominal pain. Fatty-food intolerance, back pain, dysuria, weight loss or night sweats had never occurred. The bowel habits had previously been regular. A gallbladder series and an upper . . .
Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease
Authors: Philipp M. Altrock, Christian Brendel, Raffaele Renella, Stuart H. Orkin, David A. Williams, Franziska Michor
Journal: American Journal of Hematology (2016)

Recent advances in gene therapy and genome-engineering technologies offer the opportunity to correct sickle cell disease (SCD), a heritable disorder caused by a point mutation in the β-globin gene. The developmental switch from fetal γ-globin to adult β-globin is governed in part by the transcription factor (TF) BCL11A. This TF has been proposed as a therapeutic target for reactivation of γ-globin and concomitant reduction of β-sickle globin. In this and other approaches, genetic alteration of a portion of the hematopoietic stem cell (HSC) compartment leads to a mixture of sickling and corrected red blood cells (RBCs) in periphery. To reverse the sickling phenotype, a certain proportion of corrected RBCs is necessary; the degree of HSC alteration required to achieve a desired fraction of corrected RBCs remains unknown. To address this issue, we developed a mathematical model describing aging and survival of sickle-susceptible and normal RBCs; the former can have a selective survival advantage leading to their overrepresentation. We identified the level of bone marrow chimerism required for successful stem cell-based gene therapies in SCD. Our findings were further informed using an experimental mouse model, where we transplanted mixtures of Berkeley SCD and normal murine bone marrow cells to establish chimeric grafts in murine hosts. Our integrative theoretical and experimental approach identifies the target frequency of HSC alterations required for effective treatment of sickling syndromes in humans. Our work replaces episodic observations of such target frequencies with a mathematical modeling framework that covers a large and continuous spectrum of chimerism conditions. Am. J. Hematol. 91:931-937, 2016. © 2016 Wiley Periodicals, Inc.